Raphael Pharmaceutical Inc. Stock

Equities

RAPH

US27785B2088

Biotechnology & Medical Research

Market Closed - OTC Markets 09:39:57 2024-05-31 EDT 5-day change 1st Jan Change
1.64 USD +6.49% Intraday chart for Raphael Pharmaceutical Inc. -.--% +64.00%
Sales 2022 - Sales 2023 - Capitalization 18.5M 25.42M
Net income 2022 -3M -4.12M Net income 2023 -1M -1.37M EV / Sales 2022 * -
Net cash position 2022 288K 396K Net cash position 2023 230K 316K EV / Sales 2023 -
P/E ratio 2022 *
-
P/E ratio 2023
-13 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 48.54%
More Fundamentals * Assessed data
Dynamic Chart
1 day+6.49%
1 month+64.00%
3 months+64.00%
6 months+64.00%
Current year+64.00%
More quotes
1 month
1.00
Extreme 1
1.64
Current year
1.00
Extreme 1
1.64
1 year
0.60
Extreme 0.6
1.67
3 years
0.60
Extreme 0.6
2.50
5 years
0.60
Extreme 0.6
2.50
10 years
0.60
Extreme 0.6
2.50
More quotes
Raphael Pharmaceutical Inc. is a pharmaceutical drug research and development company. The Company is focused on the discovery and clinical development of life-improving drug therapies based on cannabinoids, including cannabidiol (CBD) oil. The Company is in pre-clinical development stage for its lead product candidate, rheumatoid arthritis (RA), for the treatment of RA. In addition, the Company is also developing a pharmaceutical drug product for the treatment of hyperinflammatory syndrome inflammation related to COVID-19. The Company’s discovery platform focuses the use of CBD oil, one of the cannabinoids in cannabis plants, as the active pharmaceutical ingredient (API), for its RA product candidate and COVID-19 product candidate.
More about the company